Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1696 to 1710 of 1995 results for nice guidelines

  1. Type 1 diabetes: insulin degludec (ESNM24)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Withdrawn advice

  2. Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  3. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

    This evidence summary has been updated and replaced by NICE guideline NG201.

    Withdrawn advice

  4. Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  5. Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

    This evidence summary has been updated and replaced by NICE guideline NG117.

    Withdrawn advice

  6. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

    Withdrawn advice

  7. Chronic pain: oral ketamine (ESUOM27)

    This evidence summary has been updated and replaced by NICE guideline NG193.

    Withdrawn advice

  8. Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

    This evidence summary has been updated and replaced by NICE guideline NG131.

    Withdrawn advice

  9. Multiple long-term conditions: falls prevention advice (IND209)

    This indicator has been removed following the publication of NICE guideline NG249.

    Withdrawn indicator

  10. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

    Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA423

  11. SeQuent Please balloon catheter for in-stent coronary restenosis (MTG1)

    This medical technologies guidance has been replaced by the recommendations in the NICE guideline on acute coronary syndromes.

    Withdrawn guidance

  12. What is the clinical effectiveness of topical treatments (antibiotics and antiseptics) compared with oral antibiotics for the treatment of infected leg ulcer?

    (which may have led to antimicrobial resistance). In line with the NICE guideline on antimicrobial stewardship: systems and...

    Research recommendation
    Published
    17 March 2020

  13. Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

    This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).

    Withdrawn advice

  14. Sleepio to treat insomnia and insomnia symptoms (HTG624)

    Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.

    HealthTech guidance
    Published
    20 May 2022
    View recommendations

    Sections for HTG624

  15. Generalised anxiety disorder: quetiapine (ESUOM12)

    This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.

    Withdrawn advice